The highest levels of expression were found in grade II astrocytomas (22-fold increase, n = 2), whereas 4-fold increases were detected in grade III astrocytomas (n = 3), confirming that RRAS2 is more strongly overexpressed in lower-grade tumors. The gene discussed is RRAS2; the disease is astrocytoma (excluding glioblastoma).